| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Halftime Report Final Trades,” Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, LLC, picked Kimberly-Clark Corporation (NYSE:KMB).
“[Kimberly-Clark] is still oversold after the Kenvue announcement,” Harrington says, citing its 5% dividend yield.
Lending support to her choice, Argus Research analyst Taylor Conrad, on Thursday, upgraded Kimberly-Clark from Hold to Buy and announced a $120 price target.
Bill Baruch, founder and president of both Blue Line Capital and Blue Line Futures, named Thermo Fisher Scientific Inc. (NYSE:TMO) as his final trade.
As per the recent news, Thermo Fisher Scientific, on Oct. 29, inked a deal to acquire Clario Holdings for $8.875 billion in cash, plus potential future earnout and other performance-based payments.
Don't forget to check out our premarket coverage here
Kari Firestone, co-founder of Aureus Asset Management, picked Westinghouse Air Brake Technologies Corporation (NYSE:WAB) as her final trade.
BofA Securities analyst Ken Hoexter, on Thursday, maintained a Buy rating on Westinghouse Air Brake and raised the price target from $228 to $233.
Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he likes Berkshire Hathaway Inc. (NYSE:BRK), which is back on the upswing after a whole slew of Wall Street commentary.
Supporting his view, UBS analyst Brian Meredith maintained a Buy rating on Berkshire Hathaway on Nov. 3 and raised the price target from $593 to $595.
Price Action:
Check This Out:
Image : Shutterstock
